Handa is a profitable specialty pharmaceutical company that develops and commercializes clinically differentiated drugs, with a particular focus in Oncology and CNS. Handa is seeking to acquire, in-license or co-promote late-stage or approved products in the US. Its latest product acquisition was Phyrago, indicated for CML and ALL, for US$ 30m cash in January 2025.